<DOC>
	<DOC>NCT01303445</DOC>
	<brief_summary>The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d. at steady state on the pharmacokinetics of dipyridamole and the pharmacodynamics of ASA-induced platelet aggregation inhibition (components of Aggrenox®) when administered every 12 hours at steady state.</brief_summary>
	<brief_title>Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers</brief_title>
	<detailed_description>Purpose:</detailed_description>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
	<criteria>Inclusion criteria: 1. Healthy males and females according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure(BP), pulse rate (PR)), 12lead ECG, clinical laboratory tests 2. BMI &gt;18.5 and BMI &lt;32 kg/m2 (Body Mass Index) Exclusion criteria: 1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance in the opinion of the PI 2. Any evidence of a clinically relevant concomitant disease 3. Clinically significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, hormonal, or hematologic (including a history of abnormal bruising) disorders in the opinion of the PI 4. Surgery of the gastrointestinal tract that might impair drug absorption 5. Clinically significant diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts. 7. Chronic or relevant acute infections 8. History of relevant allergy/hypersensitivity (including allergy to study drugs or its excipients, or reactions to related drugs [e.g., nonsteroidal antiinflammatory drugs]) 9. Intake of drugs with a long halflife (¿24 hours) within one month, or less than 10 half lives of the respective drug, prior to study drug administration or during the trial 10. Use of drugs which might reasonably influence the results of the trial (including OTC antacids) based on the knowledge at the time of protocol preparation within 14 days prior to administration or during the trial 11. Participation in another trial with an investigational drug within two months prior to administration or during the trial 12. Tobacco use within the 90 days prior to checkin and throughout the study 13. Alcohol abuse within the past 2 years 14. Drug abuse within the past 2 years 15. Blood donation or other significant blood loss within 56 days (inclusive) prior to screening, or plasma donation within 7 days (inclusive) prior to study drug administration, or during the trial 16. Excessive physical activities (within one week prior to first drug administration or during the trial) 17. Any laboratory value outside the reference range that is of clinical relevance in the opinion of the PI; including positive virology, or urine drug screen, or positive fecal occult blood test 18. Inability to comply with dietary regimen of trial site 19. In the opinion of the investigator it would be in the best interest of the subject to be excluded from participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>